St. Jude Medical Gets FDA Pre-Market Approval for Spinal Cord Stimulator

 
St. Jude Medical announced that its Protégé spinal cord stimulator has received pre-market approval from the U.S. Food and Drug Administration, according to a NASDAQ report.

Advertisement

The Protégé spinal cord stimulator is intended for alleviating chronic pain and is the first neurostimulation system that can be upgraded without the need of a surgical replacement of the device. It provides access to therapies, stimulation modes, diagnostics and other features through software upgrades, according to the report.

More Articles on Devices:

Mazor Robotics 2013 Net Loss Shoots to $20M
Advancement in Lateral Spine Technology: Q&A with Vertebral Technologies, Inc. CEO Dr. Jeffrey Felt
EDGE Orthopaedics Receives FDA 510(k) Clearance for BITE Compression Screws

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • Stryker CEO Kevin Lobo’s total compensation was $21.4 million in 2025, according to a recent Securities and Exchange Commission proxy filing.…

  • John DeFord, PhD, is stepping down from Globus Medical’s board of directors, according to a March 23 news release. His…

Advertisement

Comments are closed.